LONDON, June 4 /PRNewswire/ -- The latest issue of the online journal Diabetic Hypoglycemia (http://www.hypodiab.com) features an authoritative review on sulfonylureas by Professor Ian Campbell, a leading expert in oral hypoglycemia therapy.
Professor Campbell's review focuses on sulfonylurea-induced hypoglycemia (SIH), which is a well-recognized side-effect of this class of therapy for type 2 diabetes. In the review he discusses the incidence of SIH, with particular reference to the different sulfonylureas. He also reflects on the morbidity and mortality seen with SIH, precipitating risk factors, treatment of SIH, and education of patients and medical staff in the prevention of SIH.
This issue of Diabetic Hypoglycemia also includes a case study on recurring hypoglycemia associated with glibenclamide, by Professor Campbell.
Dr Rory McCrimmon of the Editorial Board reviews the literature on blood glucose monitoring in hypoglycemia, in an editorial entitled 'What we're learning from continuous glucose monitoring.'
This issue of Diabetic Hypoglycemia also features an 'In profile' interview with Professor Stephanie Amiel, a leading expert in the use of neuroimaging in diabetes and hypoglycemia.
About the Journal
Diabetic Hypoglycemia is an influential online diabetes journal. The Editorial Board of hypoglycemia experts peer review all Journal content. The Board is led by Editor-in-Chief Professor Brian Frier (Edinburgh, UK), with Associate Editors: Professor Simon Heller (Sheffield, UK), Professor Christopher Ryan (Pittsburgh, USA) and Dr Rory McCrimmon (Yale, USA). Diabetic Hypoglycemia is published three times a year, providing an interactive forum for readers to share practical knowledge and opinions on the rapidly evolving field of hypoglycemia.
To explore the Diabetic Hypoglycemia website and its key features, our guided tour can be activated by clicking the following link: http://www.hypodiab.com/Teaser/hypodiab.html.
Diabetic Hypoglycemia is published by ESP Bioscience. Support for the journal is provided by an unrestricted educational grant from Novo Nordisk A/S (Bagsvaerd, Denmark).
About ESP Bioscience
ESP Bioscience (a division of ESP Limited, Sandhurst UK) is a publisher of novel medical information products and creates online medical communities. Working in association with its academic partners in the global healthcare community, ESP Bioscience publishes journals, books and online resources.
Contact: Rebecca Drake, Editorial Manager E: enquiries@hypodiab.com T: +44(0)1344-762531 F: +44(0)203-0514753
Contact: Rebecca Drake, Editorial Manager, E: enquiries@hypodiab.com, T: +44(0)1344-762531, F: +44(0)203-0514753
Comments